<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Chapman, Arlene B.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of the HALT PKD Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Autosomal dominant polycystic kidney disease is the fourth-leading cause of end-stage renal disease in the United States. Just-released results from the HALT Progression of Polycystic Kidney Disease (HALT PKD) Trial sought to determine whether BP control or RAAS blockade slows the progression of renal disease, as discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">49</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>